SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
SVF Investments (UK) Ltd

(Last) (First) (Middle)
69 GROSVENOR STREET

(Street)
LONDON X0 W1K 3JP

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/26/2018
3. Issuer Name and Ticker or Trading Symbol
Urovant Sciences Ltd. [ UROV ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares, $0.000037453 par value per share 20,025,098(1)(2)(3) I See Explanation(1)(2)(3)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SVF Investments (UK) Ltd

(Last) (First) (Middle)
69 GROSVENOR STREET

(Street)
LONDON X0 W1K 3JP

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SVF Holdings (UK) LLP

(Last) (First) (Middle)
69 GROSVENOR STREET

(Street)
LONDON X0 W1K 3JP

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SVF GP (Jersey) Ltd

(Last) (First) (Middle)
AZTEC GROUP HOUSE

(Street)
ST. HELIER Y9 JE4 0QH

(City) (State) (Zip)
1. Name and Address of Reporting Person*
SoftBank Vision Fund L.P.

(Last) (First) (Middle)
AZTEC GROUP HOUSE

(Street)
ST. HELIER Y9 JE4 0QH

(City) (State) (Zip)
Explanation of Responses:
1. The Reporting Persons (as defined below) do not directly own any common shares (the "Common Shares") of Urovant Sciences, Ltd. (the "Issuer"). The Reporting Persons acquired Roivant Sciences Ltd. ("Roivant") common shares on September 6, 2017. Roivant directly holds the 20,025,098 Common Shares reported herein. Due to certain governance arrangements set forth in Roivant's bye-laws, so long as there is at least one independent director as a member of the Roivant Board, of which there are currently two independent directors, the Reporting Persons, voting unanimously with three other major shareholders of Roivant, has the right to override certain decisions of the Roivant Board, including with respect to dispositions of the Common Shares. As a result, the Reporting Persons may be deemed to have beneficial ownership over the Common Shares held by Roivant.
2. The Roivant common shares are held directly by SVF Investments (UK) Limited ("SVF Investments"), which is a wholly owned subsidiary of SVF Holdings (UK) LLP ("SVF Holdings"), which is a wholly owned subsidiary of SoftBank Vision Fund L.P. ("SoftBank Vision Fund"). SVF GP (Jersey) Limited ("SVF GP"), is the general partner of SoftBank Vision Fund. SVF Investments, SVF Holdings, SoftBank Vision Fund and SVF GP are referred to herein collectively as the "Reporting Persons". SVF Holdings may be deemed to share dispositive power over the Common Shares as the sole shareholder of SVF Investments, SoftBank Vision Fund may be deemed to share dispositive power over the Common Shares as the Managing Member of SVF Holdings, and SVF GP may be deemed to share dispositive power over the Common Shares as the general partner of SVF Holdings.
3. The Reporting Persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Remarks:
/s/ Karen Ubell-Attorney-in-Fact 09/26/2018
/s/ Karen Ubell-Attorney-in-Fact 09/26/2018
/s/ Karen Ubell-Attorney-in-Fact 09/26/2018
/s/ Karen Ubell-Attorney-in-Fact 09/26/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes
 and appoints Karen Ubell, the undersigned's true and lawful 
attorneys-in fact and agent to:

(1) execute for and on behalf of the undersigned, an officer, 
director or holder of 10% of more of a registered class of securities
 of Urovant Sciences Ltd. (the "Company"), Forms 3, 4 and 5 in accordance
 with Section 16(a) of the Securities Exchange Act of 1934, 
as amended (the "Exchange Act") and the rules thereunder and any form 13D or
13G; and

(2) do and perform any and all acts for and on behalf of the undersigned 
that may be necessary or desirable to complete and execute such Form 3, 4 or 5 
or any Form 13D or 13G, complete and execute any amendment or amendments
thereto, and timely file such forms or amendments with the United States
Securities and Exchange Commission and any stock exchange or similar authority.


The undersigned hereby grants to such attorney-in-fact 
full power and authority to doand perform any and every act and thing
whatsoever requisite, necessary, or proper to be
done in the exercise of any of the rights and powers 
herein granted, as fullyto all intents and purposes as the 
undersigned might or could do if personally
present, with full
 power of substitution or revocation 
(subject to the undersigned's written approval in each case),
hereby ratifying and confirming all that such attorney-in-fact, or such 
attorney-in-fact's substitute or substitutes, 
shall lawfully do or cause to be done by virtue of this power 
of attorney and the rights and powers herein granted.  

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving 
in such capacity at the request of the undersigned, are not assuming, 
nor is the Company assuming, any of the undersigned's 
responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect 
until the earliest to occur of (a) 6 months from the date of 
its execution; (b) the undersigned is no longer 
required to file Forms 3, 4 and 5 or 13G and 13D with respect 
to the undersigned's holdings of and transactions in securities issued by the 
Company, (b) revocation by the undersigned 
in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to 
any attorney-in-fact individually, until such attorney-in-fact shall no 
longer be employed by the Company.

	The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Limited Power of Attorney.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney 
to be executed as of this 24th day of September, 2018.
       
Yours Truly, 

SVF INVESTMENTS (UK) LIMITED

By /s/ Jonathan Olof Bullock	
Name Jonathan Olof Bullock		
Title Director	

SVF HOLDINGS (UK) LLP
By Softbank Vision Fund L.P., its Managing Member
By SVF GP (Jersey) Limited, Its General Partner

By /s/ Jonathan Olof Bullock	
Name Jonathan Olof Bullock		
Title Director		


SVF GP (JERSEY) LIMITED

By /s/ Jonathan Olof Bullock	
Name Jonathan Olof Bullock		
Title Director		


SOFTBANK VISION FUND L.P.
By  SVF GP (Jersey) Limited, Its General Partner

By /s/ Jonathan Olof Bullock	
Name Jonathan Olof Bullock		
Title Director